Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

uity (BCVA) at week 36. Secondary outcome measures include the proportion of participants who gain ≥15 letters in BCVA, the proportion of participants with complete resolution of intra- and subretinal fluid, and the proportion of participants with no leakage on fluorescein angiography. &nbsp Wet AMD is a leading cause of vision loss in people aged 50 and older. Current treatment options for wet ..